

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 July 2004 (01.07.2004)

PCT

(10) International Publication Number
WO 2004/055175 A1

(51) International Patent Classification⁷: C12N 5/08

(21) International Application Number:
PCT/NO2003/000335

(22) International Filing Date: 7 October 2003 (07.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20024853 8 October 2002 (08.10.2002) NO

CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant and
(72) Inventor: TJØTTA, Enok [NO/NO]; Høyenhallsvingen 23, N-0667 Oslo (NO).

(74) Agent: KRISTIANSEN, Ewy; Zacco Norway AS, P.O. Box 765, Sentrum, N-0106 Oslo (NO).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR SELECTION OF COMPOUNDS WHICH INHIBIT CLONAL CELL GROWTH AND USE THEREOF

(57) Abstract: A three step method for selection and testing of compounds inhibiting clonal cell growth, consisting of 1) screening for substances that inhibit clonal growth in a culture, 2) in the same culture, testing whether a high local cell concentration (collocation) will decrease the inhibiting effect of such substances on clonal cell growth and 3) testing if export of metastatic cells from a tumour site could be locked by such substances. It should then be possible to decrease or even abolish the development of malignant disease or metastasis from primary tumours and development of benign tumours including atheromas in arteries. The method may also detect compounds that increase clonal growth. These compounds might possess carcinogenic properties or could be used for stimulation of a failing immune system.

WO 2004/055175 A1